Literature DB >> 22089933

Interactions of amyloid β peptide 1-40 and cerebrosterol.

Zdena Krištofiková1, Zdeněk Kříž, Daniela Rípová, Jaroslav Koča.   

Abstract

Amyloid β peptides appear to play a role in physiological processes; however, they are also involved in the pathogenesis of Alzheimer disease. Their actions under normal conditions are probably mediated by soluble monomeric L-isoforms at low concentrations, perhaps via highly specific interactions. On the contrary, toxic effects of aggregated natural L-isoforms/synthetic D-isoforms on membranes are very similar, but synthetic reverse/random L: -isoforms without pronounced aggregation properties are not toxic. Our previous work reported interactions of non-aggregated/aggregated L-isoforms of amyloid β peptides 1-40/1-42 with racemic 24-hydroxycholesterol. In this study, stereospecificity in the interactions of natural 24(S)hydroxycholesterol (cerebrosterol) or synthetic 24(R)hydroxycholesterol with soluble fragment 1-40 was evaluated by means of an in vitro test based on increased vulnerability of the hemicholinium-3 sensitive high-affinity choline uptake system in rat hippocampal cholesterol-depleted synaptosomes to the actions of amyloid β; computational simulations were also performed. Our results suggest that: (1) 24(S)hydroxycholesterol interacts with L-peptide 1-40 but not with the reverse L-peptide 40-1, (2) 24(R)hydroxycholesterol does not interact with L-peptide 1-40 or reverse 40-1, and (3) both enantiomers can probably interact with D-peptide 1-40. Therefore, the binding of 24(S)hydroxycholesterol is not fully stereospecific and the interaction could not reflect a physiological mechanism. Data from the computational simulation indicate that the hydrophobic core of the amyloid β molecule interacts with the hydrophobic part of 24(S)hydroxycholesterol, but no hydrogen bonds with high stability were found. Using this procedure, globular amyloid β could retain 24(S)hydroxycholesterol and thus contribute to its pathological accumulation in the brains of patients with Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089933     DOI: 10.1007/s11064-011-0650-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

Review 1.  Living with the enemy: a physiological role for the beta-amyloid peptide.

Authors:  José A Esteban
Journal:  Trends Neurosci       Date:  2004-01       Impact factor: 13.837

2.  Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms.

Authors:  Jianyin Shao; Stephen W Tanner; Nephi Thompson; Thomas E Cheatham
Journal:  J Chem Theory Comput       Date:  2007-11       Impact factor: 6.006

Review 3.  Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link?

Authors:  D S Auld; S Kar; R Quirion
Journal:  Trends Neurosci       Date:  1998-01       Impact factor: 13.837

4.  Profile of changes in lipid bilayer structure caused by beta-amyloid peptide.

Authors:  J J Kremer; D J Sklansky; R M Murphy
Journal:  Biochemistry       Date:  2001-07-24       Impact factor: 3.162

5.  The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-beta peptide but not aggregated, cytotoxic amyloid-beta peptide.

Authors:  K Boland; M Behrens; D Choi; K Manias; D H Perlmutter
Journal:  J Biol Chem       Date:  1996-07-26       Impact factor: 5.157

6.  An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease.

Authors:  S D Yan; J Fu; C Soto; X Chen; H Zhu; F Al-Mohanna; K Collison; A Zhu; E Stern; T Saido; M Tohyama; S Ogawa; A Roher; D Stern
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

7.  Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease.

Authors:  Heike Kölsch; D Lütjohann; M Ludwig; A Schulte; U Ptok; F Jessen; K von Bergmann; M L Rao; W Maier; R Heun
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

8.  CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism.

Authors:  Heike Kölsch; Dieter Lütjohann; Frank Jessen; Julius Popp; Frank Hentschel; Peter Kelemen; Sandra Schmitz; Wolfgang Maier; Reinhard Heun
Journal:  Eur Psychiatry       Date:  2009-03-16       Impact factor: 5.361

9.  Stereospecific interactions are necessary for Alzheimer disease amyloid-β toxicity.

Authors:  Giuseppe D Ciccotosto; Deborah J Tew; Simon C Drew; Danielle G Smith; Timothy Johanssen; Varsha Lal; Tong-Lay Lau; Keyla Perez; Cyril C Curtain; John D Wade; Frances Separovic; Colin L Masters; Jeffrey P Smith; Kevin J Barnham; Roberto Cappai
Journal:  Neurobiol Aging       Date:  2009-03-25       Impact factor: 4.673

Review 10.  Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease.

Authors:  Yann Verdier; Márta Zarándi; Botond Penke
Journal:  J Pept Sci       Date:  2004-05       Impact factor: 1.905

View more
  2 in total

1.  Protein τ-mediated effects on rat hippocampal choline transporters CHT1 and τ-amyloid β interactions.

Authors:  Zdena Kristofikova; Daniela Ripova; Katerina Hegnerová; Jana Sirova; Jiri Homola
Journal:  Neurochem Res       Date:  2013-07-04       Impact factor: 3.996

2.  Sex-Dependent Changes in Striatal Dopamine Transport in Preadolescent Rats Exposed Prenatally and/or Postnatally to Methamphetamine.

Authors:  Jana Sirova; Zdenka Kristofikova; Monika Vrajova; Michaela Fujakova-Lipski; Daniela Ripova; Jan Klaschka; Romana Slamberova
Journal:  Neurochem Res       Date:  2016-04-01       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.